We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics’ (DGX - Free Report) first-quarter 2017 adjusted earnings per share (EPS) of $1.33 came in 13.7% ahead of the Zacks Consensus Estimate and exceeded the year-ago number by 17.7%.
Adjusted EPS in the reported quarter excludes charges related to restructuring and integration, retirement of debtas well as amortization expenses. Reported EPS in the first quarter came in at $1.16, representing a year-over-year surge of 63.4%.
Reported revenues for the first quarter inched up 1.9% year over year to $1.89 billion, ahead the Zacks Consensus Estimate of $1.87 billion. According to the company, the year-over-year improvement came on the back of expanding relationships with hospital health systems and strength in several of the company’s advanced diagnostic offerings.
Volume (measured by the number of requisitions) increased 3.5% year over year during the first quarter. Revenue per requisition, however, was down 0.2%. Diagnostic information services revenues in the quarter grew 3.2% on a year-over-year basis to $1.81 billion.
Quest Diagnostics Incorporated Price, Consensus and EPS Surprise
Among operating expenses, cost of services during the reported quarter was $1.16 billion, up 1.8% year over year. Gross margin came in at 38.7%, a rise of 6 basis points (bps) year over year.
Selling, general and administrative expenses dropped 1.1% to $437 million in the reported quarter. Adjusted operating margin showed an improvement of 77 bps to 15.6%.
Quest Diagnostics exited the first quarter with cash and cash equivalents of $367 million, which marked a 2.2% rise from the year-ago quarter. Net cash provided by operating activities was $196 million compared with $153 million in the year-ago period.
In the first quarter, the company repurchased 1.6 million shares for $150 million. As of Mar 31, 2017, Quest Diagnostics was left with $1.2 billion of authorization under the approved share repurchase plan.
Outlook
Quest Diagnostics reiterated its full-year 2017 revenue guidance. The company expects full-year revenues to be within the range of $7.64 billion to $7.72 billion (annualized growth of 2–3%). The current Zacks Consensus Estimate for revenues is pegged at $7.67 billion, close to the lower end of the company’s guided range.
In addition, the company’s 2017 adjusted EPS range has been raised to $5.45–$5.60 from the earlier forecast of $5.37–$5.52. The Zacks Consensus Estimate of $5.44 remains below this range.
Operating cash flow for 2017 is expected to reach $1.1 billion, unchanged from previous guidance. The current estimates for capital expenditure remain within the range of $250–$300 million (unchanged).
Our Take
Quest Diagnostics’ first-quarter earnings and revenues duly exceeded the Zacks Consensus Estimate. The company is currently refocusing on its core diagnostic information services business and working on delivering disciplined capital deployment.
We are also highly optimistic about the company’s focus on continued execution of its five-point strategy. According to Quest Diagnostics, its planned divestiture of the Focus Diagnostics products business is part of its broader strategy to refocus on diagnostic information services. In addition, several new relationships with hospitals and integrated delivery networks were the other growth drivers. Particularly, the company is positive about its recent agreement with PeaceHealth in the Pacific Northwest, which is expected to further bolster growth, later in 2017.
However, over the past several quarters, the overall soft industry trends, leading to a low volume environment, acted as a dampener for the company.
Zacks Rank & Key Picks
Currently, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Inogen has a long-term expected earnings growth rate of 17.50%. The stock registered an impressive one-year return of 64.2%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock registered a solid one-year return of roughly 21.3%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last three–five years of actual earnings) of almost 22%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
Quest Diagnostics (DGX) Tops Q1 Earnings, Raises '17 View
Quest Diagnostics’ (DGX - Free Report) first-quarter 2017 adjusted earnings per share (EPS) of $1.33 came in 13.7% ahead of the Zacks Consensus Estimate and exceeded the year-ago number by 17.7%.
Adjusted EPS in the reported quarter excludes charges related to restructuring and integration, retirement of debtas well as amortization expenses. Reported EPS in the first quarter came in at $1.16, representing a year-over-year surge of 63.4%.
Reported revenues for the first quarter inched up 1.9% year over year to $1.89 billion, ahead the Zacks Consensus Estimate of $1.87 billion. According to the company, the year-over-year improvement came on the back of expanding relationships with hospital health systems and strength in several of the company’s advanced diagnostic offerings.
Volume (measured by the number of requisitions) increased 3.5% year over year during the first quarter. Revenue per requisition, however, was down 0.2%. Diagnostic information services revenues in the quarter grew 3.2% on a year-over-year basis to $1.81 billion.
Quest Diagnostics Incorporated Price, Consensus and EPS Surprise
Quest Diagnostics Incorporated Price, Consensus and EPS Surprise | Quest Diagnostics Incorporated Quote
Among operating expenses, cost of services during the reported quarter was $1.16 billion, up 1.8% year over year. Gross margin came in at 38.7%, a rise of 6 basis points (bps) year over year.
Selling, general and administrative expenses dropped 1.1% to $437 million in the reported quarter. Adjusted operating margin showed an improvement of 77 bps to 15.6%.
Quest Diagnostics exited the first quarter with cash and cash equivalents of $367 million, which marked a 2.2% rise from the year-ago quarter. Net cash provided by operating activities was $196 million compared with $153 million in the year-ago period.
In the first quarter, the company repurchased 1.6 million shares for $150 million. As of Mar 31, 2017, Quest Diagnostics was left with $1.2 billion of authorization under the approved share repurchase plan.
Outlook
Quest Diagnostics reiterated its full-year 2017 revenue guidance. The company expects full-year revenues to be within the range of $7.64 billion to $7.72 billion (annualized growth of 2–3%). The current Zacks Consensus Estimate for revenues is pegged at $7.67 billion, close to the lower end of the company’s guided range.
In addition, the company’s 2017 adjusted EPS range has been raised to $5.45–$5.60 from the earlier forecast of $5.37–$5.52. The Zacks Consensus Estimate of $5.44 remains below this range.
Operating cash flow for 2017 is expected to reach $1.1 billion, unchanged from previous guidance. The current estimates for capital expenditure remain within the range of $250–$300 million (unchanged).
Our Take
Quest Diagnostics’ first-quarter earnings and revenues duly exceeded the Zacks Consensus Estimate. The company is currently refocusing on its core diagnostic information services business and working on delivering disciplined capital deployment.
We are also highly optimistic about the company’s focus on continued execution of its five-point strategy. According to Quest Diagnostics, its planned divestiture of the Focus Diagnostics products business is part of its broader strategy to refocus on diagnostic information services. In addition, several new relationships with hospitals and integrated delivery networks were the other growth drivers. Particularly, the company is positive about its recent agreement with PeaceHealth in the Pacific Northwest, which is expected to further bolster growth, later in 2017.
However, over the past several quarters, the overall soft industry trends, leading to a low volume environment, acted as a dampener for the company.
Zacks Rank & Key Picks
Currently, Quest Diagnostics carries a Zacks Rank #2 (Buy).
Some other stocks worth considering in the broader medical sector include Inogen Inc. (INGN - Free Report) , Hologic, Inc. (HOLX - Free Report) and Sunshine Heart Inc . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. The stock registered an impressive one-year return of 64.2%.
Hologic has a long-term expected earnings growth rate of 11.33%. The stock registered a solid one-year return of roughly 21.3%.
Sunshine Heart posted a positive earnings surprise of 58.24% in the last reported quarter. The stock has a stellar EPS growth record (last three–five years of actual earnings) of almost 22%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>